FDA Antidepressant Suicide Report May Have Been Suppressed – Sen. Grassley
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Finance Committee staffers are requesting a meeting with FDA to discuss the alleged suppression of an internal report on suicide-related events in children taking antidepressants.
You may also be interested in...
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says
FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says
FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.
House Antidepressants Hearing To Include Six FDA Witnesses
House Energy & Commerce/Oversight Subcommittee hearing Sept. 23 will address FDA’s review of pediatric antidepressant data and is structured to pit the testimony of FDA Epidemiologist Andrew Mosholder against other agency officials.